Nasdaq

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy – – Overall response rate (ORR) of 83% ...
The Globe and Mail

Century Therapeutics’ CALiPSO-1 Study: A Promising Step in Autoimmune Disease Treatment

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Century Therapeutics, Inc. is conducting ...
Nasdaq

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by ...

- Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - - ...
Lupus Foundation of America

CALiPSO-1

The purpose of this study is to evaluate the safety and efficacy of CNTY-101, an investigational “off-the-shelf” CD19 Chimeric Antigen Receptor (CAR) Natural Killer (NK)-cell therapy, in participants ...